Good day, 360!
Here are some of our top movers today. And don’t forget to join us in Market Masters – the hottest trading room around 🔥. Be the best prepared trader on the Street!
FOCUS LIST🔎
BTM – Up over 24% in pre as Bitcoin makes new all-time highs
NVX – Up over 15% in pre after signing offtake agreement to supply synthetic graphite to Stellantis
AUTL – Up over 9% in pre after FDD grants marketing approval for AUCATZYL® for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia
*sponsored by Four Nines gold
This Stock is Up 220% and Primed for the Next Breakout
Bank of America analysts predict gold will hit $3,000 by 2025 — and this hidden gold stock is set to benefit.
With gold’s post-election dip, now could be a good opportunity to consider adding to your portfolio. Savvy investors understand the value of holding gold and gold stocks.
This stock has made impressive gains in recent years, and with insiders continuing to buy, it’s one to keep on your watchlist.
P.S. The last gold stock we highlighted in this newsletter saw a strong rally, climbing over 60% just days after our feature. Be sure to keep this one on your watchlist!
This is a sponsored advertisement on behalf of Four Nines Gold. Past performance does not guarantee future results. Investing involves risk. View the full disclaimer here: https://shorturl.at/73AF8
HOTLIST🔥
BTM – Up over 24% in pre as Bitcoin makes new all-time highs
Bitcoin Depot Inc. (BTM) owns and operates a network of cryptocurrency kiosks in North America. Its customers can buy and sell bitcoin, litecoin, and ethereum cryptocurrencies using the BTM kiosk network and other services.
Over the weekend, BTM soared to new all-time highs trading above $80k per coin for the first time. In reaction to the the price move, Bitcoin related names such as COIN, MSTR, BTBT and BTM are in play this morning.
BTM traded up over 24% in the pre-market in reaction to the big move in Bitcoin over the weekend.
The $1.96 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $2.10, $2.22 and then the pre-market high at $2.26. Beyond that, $2.50, $2.70 and $2.85 come into play.
Below $1.96, targets to the downside are $1.91, $1.81 and then a gap fill at $1.74.
NVX – Up over 15% in pre after signing offtake agreement to supply synthetic graphite to Stellantis
NOVONIX Limited (NVX) provides battery materials and development technology for battery manufacturers, materials companies, automotive original equipment manufacturers (OEMs), and consumer electronics manufacturers in North America, Asia, Australia, and Europe.
Overnight, the company announcedthe signing of a binding offtake agreement for a minimum of 86,250 tonnes, up to a target volume of 115,000 tonnes of high-performance synthetic graphite material. The material will be supplied to Stellantis’ cell manufacturing partners in North America over a six-year term starting in 2026 from NOVONIX’s Riverside facility and a planned expansion site.
Shares of NVX traded up over 15% in the pre-market in reaction to the news.
The first target for bulls is the pre-market high at $2.26. Beyond that, $2.49, $2.60, $2.80 and $3 come into play.
Below $2.26, targets to the downside are $2.13, $2.05, $1.95 and then a gap fill at $1.88
AUTL – Up over 9% in pre after FDD grants marketing approval for AUCATZYL® for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia
Autolus Therapeutics plc (AUTL) is a clinical-stage biopharmaceutical company that develops T cell therapies for the treatment of cancer and autoimmune diseases.
Over the weekend, the company announced the U.S. Food and Drug Administration (FDA) has granted marketing approval for AUCATZYL® (obecabtagene autoleucel) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL).
AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy)
Approval is based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL.
Shares of AUTL traded up over 9% in the pre-market in reaction to the news.
The $4.05 area was prior resistance and acted as support in the pre-market.
Above it, targets to the upside are $4.20, $4.40 and then the pre-market high at $4.89. Beyond that, $5, $5.30 and $6 come into play.
Below $4.05, targets to the downside are $3.85 a gap fill at $3.73, and then $3.60.
MARKET NEWS 📰
P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas!
Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull
DISCLAIMER: To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers’ trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
*Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
